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•	 Whole Genome 
sequencing Analysis 
Identifies a Distinctive 
Mutational spectrum in 
an Arsenic-Related Lung 
Tumor
OPTOMETRY AND VISION SCIENCE
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found genetic changes common in LUSC (e.g., higher 
copies at SOX2 locus) as well as alterations that are 
uncharacteristic of LUSCs: fewer point mutations, 
increased T>G/A>C mutations, and fewer C>A/G>T 
transversions. Also, a G>C mutation in TP53, which is 
rare in lung tumors but occurs in other arsenic-related 
cancers, was discovered in this case. The authors 
have identified a distinct mutation profile related to 
arsenic exposure in an LUSC, therefore suggesting 
that arsenic induces different molecular mechanisms 
in lung tumors compared with tobacco- or other 
carcinogen-induced lung tumors. Further studies on the 
mutation profiles of other arsenic-related cancers could 
provide insight for diagnostic and therapeutic target 
development. (p. 1451)
•	 Radiotherapy for Intubated 
Patients with Malignant 
Airway Obstruction
extubation as a result of MAO and discharge of intubated 
ICU patients to home. Primary endpoints were overall 
survival (OS) and extubation success. Secondary 
endpoints were discharge rates from the ICU and to home. 
Of 26 patients, 27% were extubated; all were discharged 
from the ICU and six were discharged home. Median OS 
of 0.36 months and 6-month OS of 11% were observed. 
Higher radiation dose was predictive of prolonged OS 
(hazard ratio per 5 Gy increase: 0.74; p = 0.016) and 
associated with a trend for increased extubation success 
(odds ratio per 5 Gy increase: 0.63; p = 0.080). Taken 
together, this study suggests that RT is not futile for 
intubated patients with MAO, and could be of value 
for this population of patients as they are ineligible for 
bronchoscopic intervention. (p. 1365)
In ThIs Issue
In an effort to characterize the mutation profile of arsenic-induced 
lung tumors, Martinez and colleagues analyzed a lung squamous 
cell carcinoma (LUSC) from a never-smoker who had chronic 
arsenic exposure but had no family history of lung cancer. Using 
whole genome sequencing of the arsenic-induced tumor, they 
A 10-year retrospective study was conducted on intensive care unit 
(ICU) patients who received radiotherapy (RT) and required intubation 
and mechanical ventilation for malignant airway obstruction (MAO). 
The aim of the study was to evaluate the efficacy of RT in facilitating 
•	 CDKN2A/p16 Inactivation 
Mechanisms and Their 
Relationship to smoke 
exposure and Molecular 
Features in non–small-
Cell lung Cancer
a tight correlation of all p16 inactivating mechanisms with 
loss of its mRNA and protein expression. The frequencies 
of p16 inactivation were comparable regardless of EGFR, 
KRAS, and STK11 mutations. p16 methylation was 
associated with KRAS mutation but mutually exclusive 
of EGFR mutation. Meta-analyses to assess the impact of 
smoke exposure on p16 inactivation demonstrated a modest 
positive correlation between p16 promoter methylation and 
smoking. Further studies on the relationship of specific 
p16 inactivation mechanisms and other environmental and 
genetic factors are warranted to shed light on the different 
molecular mechanisms responsible for non–small-cell lung 
cancer development. (p. 1378)
This study evaluated the association of three CDKN2A (p16) 
inactivation mechanisms, that is, homozygous deletions, methylation of 
promoter and point mutations, with its gene products, common genetic 
mutations (EGFR, KRAS, STK11) and smoking status in 40 cell lines 
and 45 primary tumor of non–small-cell lung cancer. The data revealed 
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Ten percent to 20% of primary lung squamous cell 
carcinomas (SqCCs) harbor fibroblast growth factor 
receptor 1 (FGFR1) gene amplification, which has 
generated immense interest in its role as a potential 
therapeutic target. In this study, Craddock et al. 
sought to determine its prognostic value for early-
stage SqCC. Tissue microarrays of 147 primary lung 
SqCCs and 58 matching lymph node metastases 
were analyzed by fluorescence in situ hybridization 
to determine abnormal DNA copy number of the 
FGFR1. The results revealed 18.2% of 121 primary 
SqCCs harbored FGFR1 amplification. With 97% 
to 100% concordance rates between primary and 
matching lymph node metastases, and between two 
different lymph node metastases, no significant link 
between FGFR1 copy number abnormalities and 
clinicopathological factors was found. The authors 
concluded that FGFR1 amplification is not  
prognostic in SqCC. (p. 1371)
•	 A Phase II study 
with Cetuximab and 
Radiation Therapy for 
Patients with surgically 
Resectable esophageal and 
Gastroesophageal Junction 
Carcinomas
Becerra at al. present the results of a phase II, open-
label, single-arm, multicenter study to assess the 
efficacy and safety of cetuximab and radiation therapy 
followed by surgery in patients with resectable 
esophageal and gastroesophageal junction carcinomas. 
The primary objective of the study was to evaluate 
the pathologic complete response (pCR) rate in the 
primary tumor post treatment. Secondary objectives 
were to determine the clinical complete and partial 
response rates, and overall toxicities. Of 39 patients, 
the majority were men of an average age of 64 years, 
with performance status of 0 to 1, had adenocarcinoma, 
and had tumors in the esophagus. More than 5% of 
patients experienced grade 3 toxicities whereas 2% 
experienced grade 5 aspiration. Four deaths were 
reported. The pCR rates resulted from the cetuximab 
and radiation therapy regimen were comparable with 
that from chemotherapy and radiation therapy: 36.6% 
by intention-to-treat, 48% for patients who underwent 
esophagectomy; 67% for squamous cell carcinomas, 
and 28% for adenocarcinoma. Higher pCR was linked 
to early-stage disease (IIA 70%, IIB 29%, III 28%). The 
findings suggested this regimen to be more tolerable for 
the study population when compared with preoperative 
chemotherapy and radiation. (p. 1425)
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•	 Prognostic Value of 
Fibroblast Growth Factor 
Receptor 1 Gene Locus 
Amplification in Resected 
Lung squamous Cell 
Carcinoma
1347Copyright © 2013 by the International Association for the Study of Lung Cancer
ReseARCh WATCh
•	 ICOGen: Icotinib Versus 
Gefitinib in Previously 
Treated Advanced non–
small-Cell Lung Cancer
Icotinib, an oral EGFR inhibitor with promising efficacy 
and safety profile in early clinical trials, was compared 
with gefitinib for noninferiority in a randomized, double-
blinded phase 3 trial for advanced non–small cell lung 
cancer. Patients with prior platinum-based chemotherapy 
(n=395) were analyzed, and EGFR status was assessed 
if tissues were available. The primary endpoint, median 
progression-free survival, of patients receiving icotinib 
was 4.6 months versus 3.4 months for those receiving 
gefitinib. The most common side effects were rash (41% 
icotinib versus 49% gefitinib) and diarrhea (22% versus 
29%). Lower rate of drug-related adverse events was 
found in patients who were given icotinib. The findings 
demonstrated that icotinib was noninferior to gefitinib, 
and suggested icotinib to be a novel therapy for advanced 
non–small cell lung cancer with prior chemotherapy.
Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib 
in previously treated advanced non-small-cell lung 
cancer (ICOGEN): a randomised, double-blind phase 3 
non-inferiority trial. Lanc Oncol 2013;14:953–961.
Wu et al. conducted in vitro and in vivo analyses of the 
orally bioavailable oncokinase inhibitor, LY2801653, 
which also inhibits MET, in non–small-cell lung cancer 
(NSCLC). Both in vitro and in vivo findings showed 
that LY2801653 inhibited tumor growth as a single 
agent (by 37%–90%) or in combination with cisplatin, 
gemcitabine, or erlotinib (by 67% –86%). It was also 
shown to block proliferation, anchorage-independent 
growth, migration, and invasion by disrupting the 
constitutive activation of MET pathway signaling. The 
effect of LY2801653 was also observed in an NSCLC 
orthotopic model: 88% inhibition of primary tumor 
growth and 65% to 68% inhibition of metastasis. An 
87% longer survival time was reported in tumor-bearing 
animals in MET-dependent model versus the control. 
However, it inhibited only primary tumor growth and not 
metastasis in a MET-independent orthotopic model. The 
evidence supports clinical development of LY2801653 
for treatment of NSCLC and the different MET 
activation status of tumors could be of predictive value.
Wu W, Bi C, Credille K, et al. Inhibition of tumor 
growth and metastasis in non-small cell lung cancer 
by LY2801653, an inhibitor of several oncokinases, 
including MET. Clin Cancer Res, doi:10.1158/1078-
0432.ccr-13–1758 (2013).
•	 Multikinase Inhibitor 
Blocks Tumor Growth and 
Metastasis in non–small-
Cell Lung Cancer
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•	 Gene expression and 
Drug-sensitivity Data 
stratify squamous Cell 
Lung Cancer subtypes
might explain the prognosis of these subtypes as being 
opposite to each other. From the analysis of drug-
sensitivity data of the SqCC cell lines classified to 
each of the SqCC subtypes, it was observed that most 
of them were sensitive to one of five anticancer drugs 
(Panobinostat, 17-AAG, Irinotecan, Topotecan and 
Paclitaxel), except for secretory subtype. Basal subtype 
cell line was sensitive to PF2341066, AZD6244, and 
PD-0325901. The integration of genomic and drug-
sensitivity data for the SqCC subtypes could potentially 
guide drug repurposing, with the ultimate aim of 
improving treatment for patients bearing these subtypes.
Wu D, Pang Y, Wilkerson MD, et al. Gene-expression 
data integration to squamous cell lung cancer subtypes 
reveals drug sensitivity. Br J Cancer, doi:10.1038/
bjc.2013.452 (2013).
By integrating comprehensive data sets, Wu et al. evaluated 178 
squamous cell lung cancer (SqCC) tumor samples in an effort to 
characterize the molecular features of the four SqCC subtypes 
(primitive, classical, secretory, and basal), and map them to the 
specific time points in airway development and their response 
to therapy. Differential expression of RNAseq data and pathway 
analysis identified signature gene sets and pathways specific to the 
SqCC subtypes. The findings suggest the basal subtype to have 
originated from an earlier differentiation stage than the primitive 
subtype. It also revealed that the basal and primitive subtypes 
do not share significant pathways in the same direction, which 
•	 new Model Accurately 
Predicts Cancer on First 
Lung Low-Dose Computed 
Tomography scan
A population-based prospective study led by Terry Fox Research 
Institute has proved that, 9 out of 10 times, their new clinical risk 
calculator software accurately predicts which nodules detected on 
first lung low-dose computed tomography (LDCT) scan in high-
risk lung cancer patients are benign and malignant. They analyzed 
two cohorts of data (Pan-Canadian Early Detection of Lung Cancer 
Study and British Columbia Cancer Agency chemoprevention 
trials) with a total of 12,029 nodules from 2961 participants, who 
were current and former smokers, aged 50 to 75 years, and received 
LDCT screening. Predictors of cancer in the model were 
older age, female sex, family history of lung cancer, 
emphysema, larger nodule size, location of the nodule 
in the upper lobe, part-solid nodule type, lower nodule 
count, and spiculation. Their parsimonious and full 
multivariable logistic-regression models demonstrated 
excellent discrimination and calibration, even for 
nodules less than 10 mm. The use of this tool in LDCT 
screening could improve early detection, diagnosis, and 
treatment of lung cancer as well as reduce costs and risk 
of mortality as a result of screening.
McWilliams A, Tammemagi MC, Mayo JR, et al.  
Probability of Cancer in Pulmonary Nodules 
Detected on First Screening CT. New Engl J Medicine 
2013;369:910–919.
•	 nVALT-10 Trial: erlotinib 
Alone Versus erlotinib and 
Chemotherapy in Relapsed 
non–small-Cell Lung 
Cancer Patients
overall survival, was significantly prolonged in patients 
with NSQ histology in the combination arm (hazard 
ratio = 0.67, p=0.01). The toxicity greater than grade 2 
was significantly higher in the combination arm (55%) 
versus erlotinib alone (19%); hematological toxicity 
was only found in the combination arm. Future studies 
on combination of chemotherapy and erlotinib in which 
more than four cycles of chemotherapy treatment are 
warranted to possibly enhance the synergistic effect.
Aerts JG, Codrington H, Lankheet NAG, et al. A 
randomized phase II study comparing erlotinib versus 
erlotinib with alternating chemotherapy in relapsed non-
small-cell lung cancer patients: the NVALT-10 study. 
Ann Oncol, doi:10.1093/annonc/mdt341 (2013).
In this phase II study, 231 patients with advanced non–small-cell 
lung cancer who failed first-line chemotherapy were randomized to 
receive erlotinib alone or erlotinib intercalated with docetaxel for 
squamous or pemetrexed for nonsquamous (NSQ) patients. Primary 
endpoint was progression-free survival. The primary endpoint was 
not met (hazard ratio = 0.76, p=0.06) but a trend of an increase in 
progression-free survival was observed primarily in the NSQ group 
treated with pemetrexed and erlotinib. The secondary endpoint, 
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•	 Results of the Two 
Incidence screenings 
in the national Lung 
screening Trial
incidence screenings (rounds T1 and T2) were published 
in the New England Journal of Medicine (N Engl J 
Med 2013;369:920–931). LDCT was found to be more 
sensitive than radiography (T1: 94.4%; T2: 93.0% versus 
T2: 59.6%; T2: 63.9%) but the predictive positive value 
of LDCT was lower than that of radiography (T1: 2.4%; 
T2: 5.2% versus T1: 4.4%; T2: 6.7%). In the LDCT 
group, there was a decrease in the number of advanced 
lung cancers diagnosed (47.5%) and increase in the 
number of early-stage lung cancers diagnosed (31.1%) 
when compared with the radiology group (23.5% and 
59.1%, respectively). These findings support the use of 
LDCT in detecting more lung cancers, especially early-
stage tumors that are potentially curable, in high-risk 
population. Strategies for further improvement of the 
characteristic performance of LDCT are warranted.
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In the National Lung Screening Trial, the effect of three rounds 
of annual screenings (T0, T1, and T2) using low-dose computed 
tomography (LDCT) was compared with that of chest radiography 
in reducing mortality from lung cancer. The results from the first two 
•	 Ganetespib Granted 
Fast-Track Designation 
for non–small-Cell Lung 
Adenocarcinoma
The United States Food and Drug Administration has 
granted fast-track designation to the development 
of ganetespib, an Hsp90 inhibitor, for combination 
treatment with docetaxel in patients with metastatic 
non–small-cell lung cancer who failed one prior 
chemotherapy regimen. Ganetespib is currently being 
investigated in the GALAXY-1 Phase IIb/III all-comer 
trial and the GALAXY-2 Phase 3 trial for patients 
most likely to benefit from the treatment.
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•	 First Fully Automated IhC 
Companion Diagnostic 
Approved for ALK-Positive 
Lung Cancer Patients
The Chinese Food and Drug Administration has 
approved VENTANA ALK immunohistochemistry 
assay as the first companion diagnostic for ALK-positive 
patients with non–small-cell lung cancer eligible for 
treatment with crizotinib, an oral ALK inhibitor. The 
VENTANA ALK immunohistochemistry assay uses 
rabbit monoclonal primary antibody to identify ALK-
positive patients with non–small-cell lung cancer. 
It was proved to demonstrate 99.23% concordance 
with Abbott’s ALK break-apart fluorescence in situ 
hybridization assay in a retrospective study of 1100 
Chinese subjects.
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